Table 1.

Immune response to Bexsero® by hSBA against 4 representative strains harboring Bexsero® antigens and against clinical isolates.

Individual serum
	H44/76	NGH38	5/99	LNP24349
hSBA geometric mean titers (CI 95%)
Baseline (n = 8)	3.084 (1.668–5.704)	5.187 (1.862–14.45)	3.364 (2.012–5.622)	3.668 (2.065–6.515)
6 weeks after dose 2 (n = 8)	69.79 (24.48–199.0)	32.0 (7.243–141.4)	256 (256–256)	38.05 (16.06–90.15)
P-value (6 weeks after dose 2 vs. baseline)	0.0078**	0.0156*	0.0078**	0.0078**
1 y after dose 2 (n = 7)	4.0 (1.908–8.386)	4.876 (2.013–11.81)	35.33 (6.632–188.2)	4.0 (2.370–6.751)
P-value (1 y after dose 2 vs. baseline)	0.7261	0.9258	0.0769	0.5686
Number of people with hSBA titer ≥4 (%)
Baseline (n = 8)	3 (38%)	4 (50%)	4 (50%)	4 (50%)
After dose 2 (n = 8)	8 (100%)	7 (88%)	8 (100%)	8 (100%)
1 y after dose 2 (n = 7)	4 (57%)	4 (57%)	6 (86%)	5 (71%)
Among the people with hSBA titer ≥4 at baseline (%)
4-fold increase after dose 2 (n = 8)	3 (100%)	4 (100%)	4 (100%)	4 (100%)
4-fold increase 1 y after dose 2	0	0	2 (50%)	0